Global Inherited Metabolic Disorder Market Research Report 2023

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Inherited metabolic disorders (IMDs) are a group of genetic conditions that affect the body’s ability to metabolize certain substances, such as proteins, carbohydrates, or fats. These disorders are typically caused by mutations in specific genes that affect enzymes or transport proteins crucial for normal metabolism.

According to QYResearch’s new survey, global Inherited Metabolic Disorder market is projected to reach US$ 2121.4 million in 2029, increasing from US$ 1280 million in 2022, with the CAGR of 7.6% during the period of 2023 to 2029.

The global inherited metabolic disorder market refers to the market for diagnostic tests, treatments, therapies, and related products and services for various inherited metabolic disorders. This market encompasses a wide range of disorders, each with its diagnostic and treatment requirements. Here are some key points regarding the global inherited metabolic disorder market:
Market Growth: The market for inherited metabolic disorders has been experiencing steady growth due to various factors. Technological advancements in diagnostics, increased awareness, and better access to healthcare services in developing countries contribute to market expansion.

Prevalence: Inherited metabolic disorders are relatively rare, but collectively, they affect a significant number of individuals worldwide. Certain disorders may be more prevalent in specific populations or regions. Newborn screening programs have helped in early detection, leading to increased prevalence rates.

Diagnostic Tests: The market for diagnostic tests, including genetic testing, biochemical testing, and newborn screening, plays a vital role in identifying inherited metabolic disorders. Improvements in diagnostic techniques, such as next-generation sequencing, have enabled more accurate and rapid detection of these disorders.

Therapeutic Approaches: Treatment options for inherited metabolic disorders depend on the specific disorder and its severity. Therapies may include enzyme replacement therapy, substrate reduction therapy, gene therapy, and small molecule therapies. Research and development efforts are ongoing to explore novel treatments for these disorders.

Orphan Drugs: Many inherited metabolic disorders are classified as rare diseases or orphan diseases. This designation provides companies with incentives to develop treatments through programs like orphan drug designation and market exclusivity. These incentives have spurred investment in research and development for orphan drugs targeting inherited metabolic disorders.

Challenges: The market for inherited metabolic disorders faces challenges such as high treatment costs, limited awareness among healthcare professionals and the general population, and limited accessibility to specialized treatments in certain regions.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Inherited Metabolic Disorder market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
    Mayo Clinic
    Angeion Corporation
    Abbott U.S.
    Admera Health
    Promega Corporation
    Alomone Labs
    Bio-Rad Laboratories
    Novartis AG
    AstaReal
    Regeneron Pharmaceuticals
    Biophytis
    AbbVie
    Danone
    Pfizer
    Bristol Myers Squibb
    Biogen
    GSK plc
    Roche Holding AG

Segment by Type
    Enzyme Replacement Therapy
    Cellular Transplantation
    Small Molecule Based Therapy
    Substrate Reduction Therapy
    Gene Therapy
    Drug Therapy
    Others

Segment by Application
    Hurler Syndrome
    Niemann-Pick Disease
    Tay-Sachs Disease
    Gaucher Disease
    Fabry Disease
    Krabbe Disease
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

The Inherited Metabolic Disorder report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

 1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Inherited Metabolic Disorder Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Enzyme Replacement Therapy
        1.2.3 Cellular Transplantation
        1.2.4 Small Molecule Based Therapy
        1.2.5 Substrate Reduction Therapy
        1.2.6 Gene Therapy
        1.2.7 Drug Therapy
        1.2.8 Others
    1.3 Market by Application
        1.3.1 Global Inherited Metabolic Disorder Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Hurler Syndrome
        1.3.3 Niemann-Pick Disease
        1.3.4 Tay-Sachs Disease
        1.3.5 Gaucher Disease
        1.3.6 Fabry Disease
        1.3.7 Krabbe Disease
        1.3.8 Others
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global Inherited Metabolic Disorder Market Perspective (2018-2029)
    2.2 Inherited Metabolic Disorder Growth Trends by Region
        2.2.1 Global Inherited Metabolic Disorder Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Inherited Metabolic Disorder Historic Market Size by Region (2018-2023)
        2.2.3 Inherited Metabolic Disorder Forecasted Market Size by Region (2024-2029)
    2.3 Inherited Metabolic Disorder Market Dynamics
        2.3.1 Inherited Metabolic Disorder Industry Trends
        2.3.2 Inherited Metabolic Disorder Market Drivers
        2.3.3 Inherited Metabolic Disorder Market Challenges
        2.3.4 Inherited Metabolic Disorder Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Top Inherited Metabolic Disorder Players by Revenue
        3.1.1 Global Top Inherited Metabolic Disorder Players by Revenue (2018-2023)
        3.1.2 Global Inherited Metabolic Disorder Revenue Market Share by Players (2018-2023)
    3.2 Global Inherited Metabolic Disorder Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Inherited Metabolic Disorder Revenue
    3.4 Global Inherited Metabolic Disorder Market Concentration Ratio
        3.4.1 Global Inherited Metabolic Disorder Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Inherited Metabolic Disorder Revenue in 2022
    3.5 Inherited Metabolic Disorder Key Players Head office and Area Served
    3.6 Key Players Inherited Metabolic Disorder Product Solution and Service
    3.7 Date of Enter into Inherited Metabolic Disorder Market
    3.8 Mergers & Acquisitions, Expansion Plans

 4 Inherited Metabolic Disorder Breakdown Data by Type
    4.1 Global Inherited Metabolic Disorder Historic Market Size by Type (2018-2023)
    4.2 Global Inherited Metabolic Disorder Forecasted Market Size by Type (2024-2029)

 5 Inherited Metabolic Disorder Breakdown Data by Application
    5.1 Global Inherited Metabolic Disorder Historic Market Size by Application (2018-2023)
    5.2 Global Inherited Metabolic Disorder Forecasted Market Size by Application (2024-2029)

 6 North America
    6.1 North America Inherited Metabolic Disorder Market Size (2018-2029)
    6.2 North America Inherited Metabolic Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Inherited Metabolic Disorder Market Size by Country (2018-2023)
    6.4 North America Inherited Metabolic Disorder Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada

 7 Europe
    7.1 Europe Inherited Metabolic Disorder Market Size (2018-2029)
    7.2 Europe Inherited Metabolic Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Inherited Metabolic Disorder Market Size by Country (2018-2023)
    7.4 Europe Inherited Metabolic Disorder Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries

 8 Asia-Pacific
    8.1 Asia-Pacific Inherited Metabolic Disorder Market Size (2018-2029)
    8.2 Asia-Pacific Inherited Metabolic Disorder Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Inherited Metabolic Disorder Market Size by Region (2018-2023)
    8.4 Asia-Pacific Inherited Metabolic Disorder Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia

 9 Latin America
    9.1 Latin America Inherited Metabolic Disorder Market Size (2018-2029)
    9.2 Latin America Inherited Metabolic Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Inherited Metabolic Disorder Market Size by Country (2018-2023)
    9.4 Latin America Inherited Metabolic Disorder Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil

 10 Middle East & Africa
    10.1 Middle East & Africa Inherited Metabolic Disorder Market Size (2018-2029)
    10.2 Middle East & Africa Inherited Metabolic Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Inherited Metabolic Disorder Market Size by Country (2018-2023)
    10.4 Middle East & Africa Inherited Metabolic Disorder Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE

 11 Key Players Profiles
    11.1 Mayo Clinic
        11.1.1 Mayo Clinic Company Detail
        11.1.2 Mayo Clinic Business Overview
        11.1.3 Mayo Clinic Inherited Metabolic Disorder Introduction
        11.1.4 Mayo Clinic Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.1.5 Mayo Clinic Recent Development
    11.2 Angeion Corporation
        11.2.1 Angeion Corporation Company Detail
        11.2.2 Angeion Corporation Business Overview
        11.2.3 Angeion Corporation Inherited Metabolic Disorder Introduction
        11.2.4 Angeion Corporation Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.2.5 Angeion Corporation Recent Development
    11.3 Abbott U.S.
        11.3.1 Abbott U.S. Company Detail
        11.3.2 Abbott U.S. Business Overview
        11.3.3 Abbott U.S. Inherited Metabolic Disorder Introduction
        11.3.4 Abbott U.S. Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.3.5 Abbott U.S. Recent Development
    11.4 Admera Health
        11.4.1 Admera Health Company Detail
        11.4.2 Admera Health Business Overview
        11.4.3 Admera Health Inherited Metabolic Disorder Introduction
        11.4.4 Admera Health Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.4.5 Admera Health Recent Development
    11.5 Promega Corporation
        11.5.1 Promega Corporation Company Detail
        11.5.2 Promega Corporation Business Overview
        11.5.3 Promega Corporation Inherited Metabolic Disorder Introduction
        11.5.4 Promega Corporation Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.5.5 Promega Corporation Recent Development
    11.6 Alomone Labs
        11.6.1 Alomone Labs Company Detail
        11.6.2 Alomone Labs Business Overview
        11.6.3 Alomone Labs Inherited Metabolic Disorder Introduction
        11.6.4 Alomone Labs Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.6.5 Alomone Labs Recent Development
    11.7 Bio-Rad Laboratories
        11.7.1 Bio-Rad Laboratories Company Detail
        11.7.2 Bio-Rad Laboratories Business Overview
        11.7.3 Bio-Rad Laboratories Inherited Metabolic Disorder Introduction
        11.7.4 Bio-Rad Laboratories Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.7.5 Bio-Rad Laboratories Recent Development
    11.8 Novartis AG
        11.8.1 Novartis AG Company Detail
        11.8.2 Novartis AG Business Overview
        11.8.3 Novartis AG Inherited Metabolic Disorder Introduction
        11.8.4 Novartis AG Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.8.5 Novartis AG Recent Development
    11.9 AstaReal
        11.9.1 AstaReal Company Detail
        11.9.2 AstaReal Business Overview
        11.9.3 AstaReal Inherited Metabolic Disorder Introduction
        11.9.4 AstaReal Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.9.5 AstaReal Recent Development
    11.10 Regeneron Pharmaceuticals
        11.10.1 Regeneron Pharmaceuticals Company Detail
        11.10.2 Regeneron Pharmaceuticals Business Overview
        11.10.3 Regeneron Pharmaceuticals Inherited Metabolic Disorder Introduction
        11.10.4 Regeneron Pharmaceuticals Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.10.5 Regeneron Pharmaceuticals Recent Development
    11.11 Biophytis
        11.11.1 Biophytis Company Detail
        11.11.2 Biophytis Business Overview
        11.11.3 Biophytis Inherited Metabolic Disorder Introduction
        11.11.4 Biophytis Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.11.5 Biophytis Recent Development
    11.12 AbbVie
        11.12.1 AbbVie Company Detail
        11.12.2 AbbVie Business Overview
        11.12.3 AbbVie Inherited Metabolic Disorder Introduction
        11.12.4 AbbVie Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.12.5 AbbVie Recent Development
    11.13 Danone
        11.13.1 Danone Company Detail
        11.13.2 Danone Business Overview
        11.13.3 Danone Inherited Metabolic Disorder Introduction
        11.13.4 Danone Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.13.5 Danone Recent Development
    11.14 Pfizer
        11.14.1 Pfizer Company Detail
        11.14.2 Pfizer Business Overview
        11.14.3 Pfizer Inherited Metabolic Disorder Introduction
        11.14.4 Pfizer Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.14.5 Pfizer Recent Development
    11.15 Bristol Myers Squibb
        11.15.1 Bristol Myers Squibb Company Detail
        11.15.2 Bristol Myers Squibb Business Overview
        11.15.3 Bristol Myers Squibb Inherited Metabolic Disorder Introduction
        11.15.4 Bristol Myers Squibb Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.15.5 Bristol Myers Squibb Recent Development
    11.16 Biogen
        11.16.1 Biogen Company Detail
        11.16.2 Biogen Business Overview
        11.16.3 Biogen Inherited Metabolic Disorder Introduction
        11.16.4 Biogen Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.16.5 Biogen Recent Development
    11.17 GSK plc
        11.17.1 GSK plc Company Detail
        11.17.2 GSK plc Business Overview
        11.17.3 GSK plc Inherited Metabolic Disorder Introduction
        11.17.4 GSK plc Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.17.5 GSK plc Recent Development
    11.18 Roche Holding AG
        11.18.1 Roche Holding AG Company Detail
        11.18.2 Roche Holding AG Business Overview
        11.18.3 Roche Holding AG Inherited Metabolic Disorder Introduction
        11.18.4 Roche Holding AG Revenue in Inherited Metabolic Disorder Business (2018-2023)
        11.18.5 Roche Holding AG Recent Development

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer

List of Tables
    Table 1. Global Inherited Metabolic Disorder Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Enzyme Replacement Therapy
    Table 3. Key Players of Cellular Transplantation
    Table 4. Key Players of Small Molecule Based Therapy
    Table 5. Key Players of Substrate Reduction Therapy
    Table 6. Key Players of Gene Therapy
    Table 7. Key Players of Drug Therapy
    Table 8. Key Players of Others
    Table 9. Global Inherited Metabolic Disorder Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 10. Global Inherited Metabolic Disorder Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 11. Global Inherited Metabolic Disorder Market Size by Region (2018-2023) & (US$ Million)
    Table 12. Global Inherited Metabolic Disorder Market Share by Region (2018-2023)
    Table 13. Global Inherited Metabolic Disorder Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 14. Global Inherited Metabolic Disorder Market Share by Region (2024-2029)
    Table 15. Inherited Metabolic Disorder Market Trends
    Table 16. Inherited Metabolic Disorder Market Drivers
    Table 17. Inherited Metabolic Disorder Market Challenges
    Table 18. Inherited Metabolic Disorder Market Restraints
    Table 19. Global Inherited Metabolic Disorder Revenue by Players (2018-2023) & (US$ Million)
    Table 20. Global Inherited Metabolic Disorder Market Share by Players (2018-2023)
    Table 21. Global Top Inherited Metabolic Disorder Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inherited Metabolic Disorder as of 2022)
    Table 22. Ranking of Global Top Inherited Metabolic Disorder Companies by Revenue (US$ Million) in 2022
    Table 23. Global 5 Largest Players Market Share by Inherited Metabolic Disorder Revenue (CR5 and HHI) & (2018-2023)
    Table 24. Key Players Headquarters and Area Served
    Table 25. Key Players Inherited Metabolic Disorder Product Solution and Service
    Table 26. Date of Enter into Inherited Metabolic Disorder Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Inherited Metabolic Disorder Market Size by Type (2018-2023) & (US$ Million)
    Table 29. Global Inherited Metabolic Disorder Revenue Market Share by Type (2018-2023)
    Table 30. Global Inherited Metabolic Disorder Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 31. Global Inherited Metabolic Disorder Revenue Market Share by Type (2024-2029)
    Table 32. Global Inherited Metabolic Disorder Market Size by Application (2018-2023) & (US$ Million)
    Table 33. Global Inherited Metabolic Disorder Revenue Market Share by Application (2018-2023)
    Table 34. Global Inherited Metabolic Disorder Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 35. Global Inherited Metabolic Disorder Revenue Market Share by Application (2024-2029)
    Table 36. North America Inherited Metabolic Disorder Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 37. North America Inherited Metabolic Disorder Market Size by Country (2018-2023) & (US$ Million)
    Table 38. North America Inherited Metabolic Disorder Market Size by Country (2024-2029) & (US$ Million)
    Table 39. Europe Inherited Metabolic Disorder Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 40. Europe Inherited Metabolic Disorder Market Size by Country (2018-2023) & (US$ Million)
    Table 41. Europe Inherited Metabolic Disorder Market Size by Country (2024-2029) & (US$ Million)
    Table 42. Asia-Pacific Inherited Metabolic Disorder Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 43. Asia-Pacific Inherited Metabolic Disorder Market Size by Region (2018-2023) & (US$ Million)
    Table 44. Asia-Pacific Inherited Metabolic Disorder Market Size by Region (2024-2029) & (US$ Million)
    Table 45. Latin America Inherited Metabolic Disorder Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 46. Latin America Inherited Metabolic Disorder Market Size by Country (2018-2023) & (US$ Million)
    Table 47. Latin America Inherited Metabolic Disorder Market Size by Country (2024-2029) & (US$ Million)
    Table 48. Middle East & Africa Inherited Metabolic Disorder Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 49. Middle East & Africa Inherited Metabolic Disorder Market Size by Country (2018-2023) & (US$ Million)
    Table 50. Middle East & Africa Inherited Metabolic Disorder Market Size by Country (2024-2029) & (US$ Million)
    Table 51. Mayo Clinic Company Detail
    Table 52. Mayo Clinic Business Overview
    Table 53. Mayo Clinic Inherited Metabolic Disorder Product
    Table 54. Mayo Clinic Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 55. Mayo Clinic Recent Development
    Table 56. Angeion Corporation Company Detail
    Table 57. Angeion Corporation Business Overview
    Table 58. Angeion Corporation Inherited Metabolic Disorder Product
    Table 59. Angeion Corporation Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 60. Angeion Corporation Recent Development
    Table 61. Abbott U.S. Company Detail
    Table 62. Abbott U.S. Business Overview
    Table 63. Abbott U.S. Inherited Metabolic Disorder Product
    Table 64. Abbott U.S. Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 65. Abbott U.S. Recent Development
    Table 66. Admera Health Company Detail
    Table 67. Admera Health Business Overview
    Table 68. Admera Health Inherited Metabolic Disorder Product
    Table 69. Admera Health Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 70. Admera Health Recent Development
    Table 71. Promega Corporation Company Detail
    Table 72. Promega Corporation Business Overview
    Table 73. Promega Corporation Inherited Metabolic Disorder Product
    Table 74. Promega Corporation Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 75. Promega Corporation Recent Development
    Table 76. Alomone Labs Company Detail
    Table 77. Alomone Labs Business Overview
    Table 78. Alomone Labs Inherited Metabolic Disorder Product
    Table 79. Alomone Labs Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 80. Alomone Labs Recent Development
    Table 81. Bio-Rad Laboratories Company Detail
    Table 82. Bio-Rad Laboratories Business Overview
    Table 83. Bio-Rad Laboratories Inherited Metabolic Disorder Product
    Table 84. Bio-Rad Laboratories Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 85. Bio-Rad Laboratories Recent Development
    Table 86. Novartis AG Company Detail
    Table 87. Novartis AG Business Overview
    Table 88. Novartis AG Inherited Metabolic Disorder Product
    Table 89. Novartis AG Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 90. Novartis AG Recent Development
    Table 91. AstaReal Company Detail
    Table 92. AstaReal Business Overview
    Table 93. AstaReal Inherited Metabolic Disorder Product
    Table 94. AstaReal Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 95. AstaReal Recent Development
    Table 96. Regeneron Pharmaceuticals Company Detail
    Table 97. Regeneron Pharmaceuticals Business Overview
    Table 98. Regeneron Pharmaceuticals Inherited Metabolic Disorder Product
    Table 99. Regeneron Pharmaceuticals Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 100. Regeneron Pharmaceuticals Recent Development
    Table 101. Biophytis Company Detail
    Table 102. Biophytis Business Overview
    Table 103. Biophytis Inherited Metabolic Disorder Product
    Table 104. Biophytis Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 105. Biophytis Recent Development
    Table 106. AbbVie Company Detail
    Table 107. AbbVie Business Overview
    Table 108. AbbVie Inherited Metabolic Disorder Product
    Table 109. AbbVie Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 110. AbbVie Recent Development
    Table 111. Danone Company Detail
    Table 112. Danone Business Overview
    Table 113. Danone Inherited Metabolic Disorder Product
    Table 114. Danone Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 115. Danone Recent Development
    Table 116. Pfizer Company Detail
    Table 117. Pfizer Business Overview
    Table 118. Pfizer Inherited Metabolic Disorder Product
    Table 119. Pfizer Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 120. Pfizer Recent Development
    Table 121. Bristol Myers Squibb Company Detail
    Table 122. Bristol Myers Squibb Business Overview
    Table 123. Bristol Myers Squibb Inherited Metabolic Disorder Product
    Table 124. Bristol Myers Squibb Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 125. Bristol Myers Squibb Recent Development
    Table 126. Biogen Company Detail
    Table 127. Biogen Business Overview
    Table 128. Biogen Inherited Metabolic Disorder Product
    Table 129. Biogen Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 130. Biogen Recent Development
    Table 131. GSK plc Company Detail
    Table 132. GSK plc Business Overview
    Table 133. GSK plc Inherited Metabolic Disorder Product
    Table 134. GSK plc Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 135. GSK plc Recent Development
    Table 136. Roche Holding AG Company Detail
    Table 137. Roche Holding AG Business Overview
    Table 138. Roche Holding AG Inherited Metabolic Disorder Product
    Table 139. Roche Holding AG Revenue in Inherited Metabolic Disorder Business (2018-2023) & (US$ Million)
    Table 140. Roche Holding AG Recent Development
    Table 141. Research Programs/Design for This Report
    Table 142. Key Data Information from Secondary Sources
    Table 143. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Inherited Metabolic Disorder Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Inherited Metabolic Disorder Market Share by Type: 2022 VS 2029
    Figure 3. Enzyme Replacement Therapy Features
    Figure 4. Cellular Transplantation Features
    Figure 5. Small Molecule Based Therapy Features
    Figure 6. Substrate Reduction Therapy Features
    Figure 7. Gene Therapy Features
    Figure 8. Drug Therapy Features
    Figure 9. Others Features
    Figure 10. Global Inherited Metabolic Disorder Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 11. Global Inherited Metabolic Disorder Market Share by Application: 2022 VS 2029
    Figure 12. Hurler Syndrome Case Studies
    Figure 13. Niemann-Pick Disease Case Studies
    Figure 14. Tay-Sachs Disease Case Studies
    Figure 15. Gaucher Disease Case Studies
    Figure 16. Fabry Disease Case Studies
    Figure 17. Krabbe Disease Case Studies
    Figure 18. Others Case Studies
    Figure 19. Inherited Metabolic Disorder Report Years Considered
    Figure 20. Global Inherited Metabolic Disorder Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 21. Global Inherited Metabolic Disorder Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 22. Global Inherited Metabolic Disorder Market Share by Region: 2022 VS 2029
    Figure 23. Global Inherited Metabolic Disorder Market Share by Players in 2022
    Figure 24. Global Top Inherited Metabolic Disorder Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inherited Metabolic Disorder as of 2022)
    Figure 25. The Top 10 and 5 Players Market Share by Inherited Metabolic Disorder Revenue in 2022
    Figure 26. North America Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. North America Inherited Metabolic Disorder Market Share by Country (2018-2029)
    Figure 28. United States Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Canada Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Europe Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Europe Inherited Metabolic Disorder Market Share by Country (2018-2029)
    Figure 32. Germany Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. France Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. U.K. Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. Italy Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. Russia Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. Nordic Countries Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. Asia-Pacific Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Asia-Pacific Inherited Metabolic Disorder Market Share by Region (2018-2029)
    Figure 40. China Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Japan Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. South Korea Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Southeast Asia Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. India Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. Australia Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Latin America Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. Latin America Inherited Metabolic Disorder Market Share by Country (2018-2029)
    Figure 48. Mexico Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 49. Brazil Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 50. Middle East & Africa Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 51. Middle East & Africa Inherited Metabolic Disorder Market Share by Country (2018-2029)
    Figure 52. Turkey Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 53. Saudi Arabia Inherited Metabolic Disorder Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 54. Mayo Clinic Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 55. Angeion Corporation Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 56. Abbott U.S. Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 57. Admera Health Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 58. Promega Corporation Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 59. Alomone Labs Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 60. Bio-Rad Laboratories Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 61. Novartis AG Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 62. AstaReal Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 63. Regeneron Pharmaceuticals Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 64. Biophytis Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 65. AbbVie Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 66. Danone Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 67. Pfizer Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 68. Bristol Myers Squibb Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 69. Biogen Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 70. GSK plc Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 71. Roche Holding AG Revenue Growth Rate in Inherited Metabolic Disorder Business (2018-2023)
    Figure 72. Bottom-up and Top-down Approaches for This Report
    Figure 73. Data Triangulation
    Figure 74. Key Executives Interviewed

Inherited metabolic disorders (IMDs) are a group of genetic conditions that affect the body’s ability to metabolize certain substances, such as proteins, carbohydrates, or fats. These disorders are typically caused by mutations in specific genes that affect enzymes or transport proteins crucial for normal metabolism.

According to QYResearch’s new survey, global Inherited Metabolic Disorder market is projected to reach US$ 2121.4 million in 2029, increasing from US$ 1280 million in 2022, with the CAGR of 7.6% during the period of 2023 to 2029.

The global inherited metabolic disorder market refers to the market for diagnostic tests, treatments, therapies, and related products and services for various inherited metabolic disorders. This market encompasses a wide range of disorders, each with its diagnostic and treatment requirements. Here are some key points regarding the global inherited metabolic disorder market:
Market Growth: The market for inherited metabolic disorders has been experiencing steady growth due to various factors. Technological advancements in diagnostics, increased awareness, and better access to healthcare services in developing countries contribute to market expansion.

Prevalence: Inherited metabolic disorders are relatively rare, but collectively, they affect a significant number of individuals worldwide. Certain disorders may be more prevalent in specific populations or regions. Newborn screening programs have helped in early detection, leading to increased prevalence rates.

Diagnostic Tests: The market for diagnostic tests, including genetic testing, biochemical testing, and newborn screening, plays a vital role in identifying inherited metabolic disorders. Improvements in diagnostic techniques, such as next-generation sequencing, have enabled more accurate and rapid detection of these disorders.

Therapeutic Approaches: Treatment options for inherited metabolic disorders depend on the specific disorder and its severity. Therapies may include enzyme replacement therapy, substrate reduction therapy, gene therapy, and small molecule therapies. Research and development efforts are ongoing to explore novel treatments for these disorders.

Orphan Drugs: Many inherited metabolic disorders are classified as rare diseases or orphan diseases. This designation provides companies with incentives to develop treatments through programs like orphan drug designation and market exclusivity. These incentives have spurred investment in research and development for orphan drugs targeting inherited metabolic disorders.

Challenges: The market for inherited metabolic disorders faces challenges such as high treatment costs, limited awareness among healthcare professionals and the general population, and limited accessibility to specialized treatments in certain regions.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Inherited Metabolic Disorder market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
    Mayo Clinic
    Angeion Corporation
    Abbott U.S.
    Admera Health
    Promega Corporation
    Alomone Labs
    Bio-Rad Laboratories
    Novartis AG
    AstaReal
    Regeneron Pharmaceuticals
    Biophytis
    AbbVie
    Danone
    Pfizer
    Bristol Myers Squibb
    Biogen
    GSK plc
    Roche Holding AG

Segment by Type
    Enzyme Replacement Therapy
    Cellular Transplantation
    Small Molecule Based Therapy
    Substrate Reduction Therapy
    Gene Therapy
    Drug Therapy
    Others

Segment by Application
    Hurler Syndrome
    Niemann-Pick Disease
    Tay-Sachs Disease
    Gaucher Disease
    Fabry Disease
    Krabbe Disease
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

The Inherited Metabolic Disorder report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source